Northwest Bioth Cmn (NWBO): Price and Financial Metrics
NWBO Price/Volume Stats
| Current price | $0.71 | 52-week high | $1.27 |
| Prev. close | $0.71 | 52-week low | $0.45 |
| Day low | $0.70 | Volume | 792,202 |
| Day high | $0.73 | Avg. volume | 1,703,399 |
| 50-day MA | $0.58 | Dividend yield | N/A |
| 200-day MA | $0.70 | Market Cap | 773.92M |
NWBO Stock Price Chart Interactive Chart >
NWBO POWR Grades
- NWBO scores best on the Growth dimension, with a Growth rank ahead of 70.09% of US stocks.
- The strongest trend for NWBO is in Quality, which has been heading down over the past 179 days.
- NWBO ranks lowest in Quality; there it ranks in the 12th percentile.
NWBO Stock Summary
- NORTHWEST BIOTHERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 7.58% of US listed stocks.
- With a price/sales ratio of 308.92, NORTHWEST BIOTHERAPEUTICS INC has a higher such ratio than 98.74% of stocks in our set.
- NWBO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 6.33% of US stocks.
- If you're looking for stocks that are quantitatively similar to NORTHWEST BIOTHERAPEUTICS INC, a group of peers worth examining would be HLTH, CLXT, AIP, PACB, and TGTX.
- Visit NWBO's SEC page to see the company's official filings. To visit the company's web site, go to www.nwbio.com.
NWBO Valuation Summary
- In comparison to the median Healthcare stock, NWBO's price/sales ratio is 5819.61% higher, now standing at 301.9.
- NWBO's price/sales ratio has moved up 251.2 over the prior 243 months.
Below are key valuation metrics over time for NWBO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NWBO | 2023-05-23 | 301.9 | -11.6 | -6.4 | -7.0 |
| NWBO | 2023-05-22 | 301.9 | -11.6 | -6.4 | -7.0 |
| NWBO | 2023-05-19 | 304.4 | -11.7 | -6.5 | -7.1 |
| NWBO | 2023-05-18 | 291.8 | -11.3 | -6.2 | -6.8 |
| NWBO | 2023-05-17 | 301.4 | -11.6 | -6.4 | -7.0 |
| NWBO | 2023-05-16 | 306.9 | -11.8 | -6.5 | -7.1 |
NWBO Growth Metrics
- The 2 year cash and equivalents growth rate now stands at 811.39%.
- The 5 year net income to common stockholders growth rate now stands at 103.65%.
- Its 4 year price growth rate is now at 137.5%.
The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.086 | -55.172 | 56.586 |
| 2022-06-30 | 1.23 | -46.067 | 134.957 |
| 2022-03-31 | 1.169 | -38.018 | 169.035 |
| 2021-12-31 | 1.005 | -38.299 | 179.126 |
| 2021-09-30 | 1.508 | -37.256 | -234.493 |
| 2021-06-30 | 1.374 | -38.265 | -474.108 |
NWBO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NWBO has a Quality Grade of C, ranking ahead of 27.35% of graded US stocks.
- NWBO's asset turnover comes in at 0.045 -- ranking 328th of 682 Pharmaceutical Products stocks.
- EDSA, BLCM, and GLYC are the stocks whose asset turnover ratios are most correlated with NWBO.
The table below shows NWBO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.045 | 1 | 1.610 |
| 2021-03-31 | 0.036 | 1 | 2.337 |
| 2020-12-31 | 0.061 | 1 | 3.470 |
| 2020-09-30 | 0.112 | 1 | 3.430 |
| 2020-06-30 | 0.190 | 1 | 1.815 |
| 2020-03-31 | 0.245 | 1 | -0.306 |
Northwest Bioth Cmn (NWBO) Company Bio
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.
Latest NWBO News From Around the Web
Below are the latest news stories about NORTHWEST BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate NWBO as an investment opportunity.
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. FacilityNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and Advent BioServices, a leading contract development and manufacturing organization (CDMO) based in the UK, jointly announce that a MIA license has been approved and issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at the GMP facility in Sawston, U.K. |
Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVBNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has no banking relationship with Silicon Valley Bank (SVB) and no funds on deposit at SVB. |
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on December 30, 2022, and discussion at the Meeting (which was publicly available) about achievements in 2022 and anticipated activities in 2023. |
NWBO Stock Alert: Northwest Bio Slams Citadel Securities in New LawsuitShares of Northwest Biotherapeutics (OTCMKTS:NWBO) are in focus on Thursday. NWBO stock is up about 5% on the day and it’s got investors’ attention with a lawsuit against Citadel Securities, among other firms. Here’s the skinny. The company is accusing Citadel Securities, Susquehanna and “other Wall Street firms of driving down its stock price through a series of illicit trading tactics.” It also includes Canaccord Genuity, G1 Execution Services, GTS Securities, Instinet, Lime Trading and Virtu |
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for GlioblastomaNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported that in its Phase III clinical trial both median survival and the "long tail" of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L. The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial. |
NWBO Price Returns
| 1-mo | 22.41% |
| 3-mo | 18.33% |
| 6-mo | -25.58% |
| 1-year | 1.46% |
| 3-year | 89.33% |
| 5-year | 178.54% |
| YTD | -9.50% |
| 2022 | 12.07% |
| 2021 | -54.10% |
| 2020 | 609.63% |
| 2019 | 4.57% |
| 2018 | -12.63% |
Continue Researching NWBO
Want to do more research on Northwest Biotherapeutics Inc's stock and its price? Try the links below:Northwest Biotherapeutics Inc (NWBO) Stock Price | Nasdaq
Northwest Biotherapeutics Inc (NWBO) Stock Quote, History and News - Yahoo Finance
Northwest Biotherapeutics Inc (NWBO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...